Episode Details

Drs. Ungar and Cices discuss how to interpret long-term safety data for systemic therapies in moderate-to-severe atopic dermatitis, emphasizing the importance of balancing safety signals against the harms of uncontrolled chronic inflammation. They highlight real-world evidence—especially for JAK inhibitors and biologics like dupilumab—as increasingly reassuring, while stressing individualized risk assessment based on patient age, comorbidities, and background cardiovascular risk.